Literature DB >> 6727280

Serum gentamicin concentrations during intratracheal administration.

F Vogel, M Exner, H von Lilienfeld-Toal, N Cattelaens, M Eichelbaum.   

Abstract

In artificially ventilated patients, intratracheal aminoglycoside administration is used as a form of prophylaxis of broncho-pulmonary infections. In artificially ventilated patients with multiple organ failure, serum gentamicin concentrations were measured dependent on renal function after endotracheal administration. A standard commercial ampule of 40 mg gentamicin in a 1 ml solution was injected in undiluted form, intratracheally through the tubus , every 6 h. In the patients without renal failure, values over 1 microgram/ml were only found in certain individual cases and reached a maximum of 1.5 micrograms/ml. In patients with renal failure even after prolonged application, the average serum concentrations were between 2 and 3.5 micrograms/ml. In a very few cases, however, levels of up to 10.5 micrograms/ml were measured. The daily serum pattern revealed a distinct dependence on the administration; 1 h after administration there was an increase in the serum concentrations which decreased to the initial levels after 6 h. When patients with renal impairment are given an aminoglycoside intratracheally, serum levels of up to 10.5 micrograms/ml may be reached and thus additional systemic aminoglycoside therapy should be avoided.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6727280     DOI: 10.1007/BF01742295

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  16 in total

1.  Intratracheal gentamicin and dexamethasone for treatment of infectious tracheobronchitis in the dog.

Authors:  R V Hutchison
Journal:  Vet Med Small Anim Clin       Date:  1975-08

2.  Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation.

Authors:  J D Brain; D E Knudson; S P Sorokin; M A Davis
Journal:  Environ Res       Date:  1976-02       Impact factor: 6.498

Review 3.  Clinical pharmacokinetics of aminoglycoside antibiotics.

Authors:  J C Pechere; R Dugal
Journal:  Clin Pharmacokinet       Date:  1979 May-Jun       Impact factor: 6.447

4.  [Inhalation of gentamycin. Toxicologic and pharmacokinetic experiments in rats].

Authors:  A Hofmann; W Hameister; H Wahlig
Journal:  Int J Clin Pharmacol       Date:  1974-10

5.  [Intratracheal instillation of gentamicin. Relation between the serum levels obtained and creatininemia].

Authors:  M Peromet; E Schoutens; E Yourassowsky
Journal:  Acta Clin Belg       Date:  1972       Impact factor: 1.264

6.  [The absorption of gentamycin through the bronchial tree].

Authors:  H Regula; W Wundt; U Kleinhuber; O Wieser
Journal:  Munch Med Wochenschr       Date:  1972-05-26

7.  Endotracheally administered gentamicin for the prevention of infections of the respiratory tract in patients with tracheostomy: a double-blind study.

Authors:  J Klastersky; E Huysmans; D Weerts; C Hensgens; D Daneau
Journal:  Chest       Date:  1974-06       Impact factor: 9.410

8.  Endotracheally administered antibiotics for gram-negative bronchopneumonia.

Authors:  J Klastersky; F Carpentier-Meunier; L Kahan-Coppens; J P Thys
Journal:  Chest       Date:  1979-05       Impact factor: 9.410

9.  Pharmacokinetics of gentamicin administered intratracheally to rats.

Authors:  T Trnovec; J Navarová; M Kettner; M Gregusková; S Bezek; A Gajdosík; A Kyselová
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

10.  [Prophylaxis and treatment of respiratory tract infection in ventilated patients by endotracheal administration of aminoglycosides (author's transl)].

Authors:  F Vogel; H Werner; M Exner; M Marx
Journal:  Dtsch Med Wochenschr       Date:  1981-07-10       Impact factor: 0.628

View more
  1 in total

Review 1.  Aerosolised antibacterials for the prevention and treatment of hospital-acquired pneumonia.

Authors:  G Christopher Wood; Joseph M Swanson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.